Three Months Ended

June 30, 2015

(unaudited)

($)

Year Ended

March 31, 2015

($)

Balance due (to) Pharma and NDM at beginning of period

192,505

-

Amounts advanced to Pharma

-

567,633

Amounts received from Pharma

-

(7,692

)

Reduction in prepayments to Pharma for clinical trials

(177,794

)

(257,441

)

Amounts invoiced by Pharma to DDL and TCL

-

(106,193

)

Expenses paid by Pharma on behalf of DDL and TCL

-

134

Intellectual Property costs paid by Pharma on behalf of DDL and TCL

-

(946

)

Foreign exchange differences

(597

)

(2,990

)

Balance due from (to) Pharma and NDM at end of the period

14,114

192,505